@article{4c9c41b728da4dc6a20d0683bfac4617,
title = "Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study: Journal of Endocrinological Investigation",
abstract = "Introduction: The immune checkpoint inhibitors (ICPIs) agents anti-T lymphocytes-associated antigen 4 (CTLA-4) and anti-programmed cell death protein-1 (PD-1) and its ligands (PD-L1/PD-L2) have opened a new scenario in the treatment of cancer. These agents can induce immuno-related adverse events (irAEs), which may affect the endocrine system. Purpose: The aim of this study was to analyze the occurrence and the course of endocrine irAEs in cancer patients treated with anti-PD-1 immunotherapy. Methods: This was a retrospective, multicentre study, involving cancer patients treated with the PD-1 inhibitors nivolumab or pembrolizumab at reference Oncology Centres. One hundred and seventy-nine consecutive patients with different types of cancer (mostly non-small cell lung cancer, melanoma, kidney cancer) were included in the study. Patients had received nivolumab (70.9%) or pembrolizumab (29.1%) for 2–33 months. The study evaluated clinical data records until the established date of July 15, 2018. The primary end point was the assessment of endocrine toxicity and possible predictive factors. Results: Endocrine toxicity occurred in 54 out of 179 patients (30.2%) and was related to thyroid dysfunction, with the exception of one case of diabetes mellitus. Thyroid toxicity occurred mostly within 2 months from the initiation of immunotherapy (83% of cases). A pre-existing thyroid dysfunction was a significant predictor of disease flare. Conclusions: Thyroid alterations are frequently associated with anti PD-1 treatment in cancer patients. Regular thyroid assessment should be performed, particularly in the first months of treatment and in patients with a pre-existing thyroid disease. {\textcopyright} 2019, Italian Society of Endocrinology (SIE).",
keywords = "Cancer, Endocrine toxicity, Immunotherapy, Nivolumab, Pembrolizumab, nivolumab, pembrolizumab, thiamazole, thyroxine, immunological antineoplastic agent, monoclonal antibody, adult, aged, Article, asthenia, bladder cancer, breast cancer, cancer immunotherapy, cancer patient, diabetes mellitus, disease exacerbation, endocrine disease, endocrine toxicity, female, head and neck cancer, human, hypothyroidism, immuno related adverse event, immunopathology, kidney cancer, major clinical study, male, melanoma, multicenter study, non small cell lung cancer, polydipsia, polyuria, retrospective study, subclinical hyperthyroidism, subclinical hypothyroidism, thyroid disease, thyrotoxicosis, very elderly, kidney tumor, lung tumor, middle aged, skin tumor, young adult, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Female, Humans, Kidney Neoplasms, Lung Neoplasms, Male, Melanoma, Middle Aged, Retrospective Studies, Skin Neoplasms, Thyroid Diseases, Young Adult",
author = "E.M. Presotto and G. Rastrelli and I. Desideri and V. Scotti and S. Gunnella and N. Pimpinelli and E. Vaccher and A. Bearz and {Di Costanzo}, F. and M. Bruggia and E. Mini and M. Maggi and A. Peri",
note = "Cited By :7 Export Date: 17 February 2021 CODEN: JEIND Correspondence Address: Peri, A.; Endocrinology, Viale Pieraccini, 6, Italy; email: alessandro.peri@unifi.it Chemicals/CAS: nivolumab, 946414-94-4; pembrolizumab, 1374853-91-4; thiamazole, 60-56-0; thyroxine, 7488-70-2; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Nivolumab; pembrolizumab References: Hodi, F.S., O{\textquoteright}Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Urba, W.J., Improved survival with ipilimumab in patients with metastatic melanoma (2010) N Engl J Med, 363, pp. 711-723. , COI: 1:CAS:528:DC%2BC3cXhtVCrtrbN; Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Lebb{\'e}, C., Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study (2010) Lancet Oncol, 11, pp. 155-164. , COI: 1:CAS:528:DC%2BC3cXhtlGgtbY%3D; Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer (2012) N Engl J Med, 366, pp. 2443-2454. , COI: 1:CAS:528:DC%2BC38XhtV2rs7fN; Ribas, A., Wolchok, J.D., Combining cancer immunotherapy and targeted therapy (2013) Curr Opin Immunol, 25, pp. 291-296. , COI: 1:CAS:528:DC%2BC3sXlt1ejtb4%3D; Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Wolchok, J.D., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma (2015) N Engl J Med, 373, pp. 23-34; Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Ribas, A., Pembrolizumab versus ipilimumab in advanced melanoma (2015) N Engl J Med, 372, pp. 2521-2532. , COI: 1:CAS:528:DC%2BC2MXhtFyrsbrF; Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy (2015) J Clin Oncol, 33, pp. 1974-1982. , COI: 1:CAS:528:DC%2BC2MXhsFKmt7%2FN; Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Rittmeyer, A., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial (2016) Lancet, 387, pp. 1837-1846. , COI: 1:CAS:528:DC%2BC28XktVOltrs%3D; Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., Curiel, T.J., Segal, N.H., Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer (2016) J Clin Oncol, 34, pp. 3119-3125. , COI: 1:CAS:528:DC%2BC28XhvFertrzP; Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S.M., Gandara, D.R., OAK Study Group (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2017) Lancet, 389, pp. 255-265; Baxi, S., Yang, A., Gennarelli, R.L., Khan, N., Wang, Z., Boyce, L., Korenstein, D., Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis (2018) BMJ; Kumar, V., Chaundary, N., Garg, M., Floudas, C.S., Soni, P., Chandra, A.B., Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy (2017) Front Pharmacol; Chang, L.S., Barroso-Sousa, R., Tolaney, S.M., Hodi, F.S., Kaiser, U.B., Min, L., Endocrine toxicity of cancer immunotherapy targeting immune checkpoints (2019) Endocr Rev, 40, pp. 17-65. , PID: 30184160; Cooper, G.S., Bynum, M.L., Somers, E.C., Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases (2009) J Autoimmun, 33, pp. 197-207; Morganstein, D.L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., Larkin, J., Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma (2017) Clin Endocrinol (Oxf), 86, pp. 614-620. , COI: 1:CAS:528:DC%2BC2sXksVSktrs%3D; Scott, E.S., Long, G.V., Guminski, A., Clifton-Bligh, R.J., Menzies, A.M., Tsang, V.H., The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma (2018) Eur J Endocrinol, 178, pp. 175-182; Leonardi, G.C., Gainor, J.F., Altan, M., Kravets, S., Dahlberg, S.E., Gedmintas, L., Azimi, R., Awad, M.M., Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders (2018) J Clin Oncol, 36, pp. 1905-1912. , COI: 1:CAS:528:DC%2BC1MXitFyksr8%3D; Danlos, F.X., Voisin, A.L., Dyevre, V., Michot, J.M., Routier, E., Taillade, L., Champiat, S., Lambotte, O., Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease (2018) Eur J Cancer, 91, pp. 21-29. , COI: 1:CAS:528:DC%2BC1cXkvFOruw%3D%3D; Guaraldi, F., La Selva, R., Sam{\`a}, M.T., D{\textquoteright}Angelo, V., Gori, D., Fava, P., Fierro, M.T., Arvat, E., Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution (2018) J Endocrinol Invest, 41, pp. 549-556. , COI: 1:CAS:528:DC%2BC2sXhs1yjs77J; Patel, N.M., Michelini, V.V., Snell, J.M., Balu, S., Hoyle, A.P., Parker, J.S., Hayward, M.C., Kim, W.Y., Enhancing next-generation sequencing-guided cancer care through cognitive computing (2018) Oncologist, 23, pp. 179-185; Barroso-Sousa, R., Barry, W.T., Garrido-Castro, A.C., Hodi, F.S., Min, L., Krop, I.E., Tolaney, S.M., Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis (2018) JAMA Oncol, 4, pp. 173-182; Lee, H., Hodi, F.S., Giobbie-Hurder, A., Ott, P.A., Buchbinder, E.I., Haq, R., Tolaney, S., Min, L., Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy (2017) Cancer Immunol Res, 5, pp. 1133-1140. , COI: 1:CAS:528:DC%2BC2sXhvFWhsbrK; Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Kirkwood, J.M., Prognostic significance of autoimmunity during treatment of melanoma with interferon (2006) N Engl J Med, 354, pp. 709-718. , COI: 1:CAS:528:DC%2BD28XhsVWrsrw%3D; De Remigis, A., de Gruijl, T.D., Uram, J.N., Tzou, S.C., Iwama, S., Talor, M.V., Armstrong, T.D., Caturegli, P., Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival (2015) Int J Cancer, 136, pp. 127-137; Shah, R.R., Shah, D.R., Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology (2019) Drug Saf, 42, pp. 181-198. , COI: 1:CAS:528:DC%2BC1MXnvFOqtr8%3D; Teulings, H.E., Limpens, J., Jansen, S.N., Zwinderman, A.H., Reitsma, J.B., Spuls, P.I., Luiten, R.M., Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis (2015) J Clin Oncol, 33, pp. 773-781. , COI: 1:CAS:528:DC%2BC2MXhtVWgsrvK; Brahmer, J.R., Lacchetti, C., Schneider, B.J., Atkins, M.B., Brassil, K.J., Caterino, J.M., Chau, I., Thompson, J.A., Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline (2018) J Clin Oncol, 36, pp. 1714-1768. , COI: 1:CAS:528:DC%2BC1MXhvV2iur0%3D; Califano, R., Lal, R., Lewanski, C., Nicolson, M.C., Ottensmeier, C.H., Popat, S., Hodgson, M., Postmus, P.E., Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice (2018) Future Oncol, 14, pp. 2415-2431. , COI: 1:CAS:528:DC%2BC1cXhslaqt7fP; Ruggeri, R.M., Campenn{\`i}, A., Giuffrida, G.P., Trimboli, L., Giovanella, F., Cannav{\`o}, T.S., Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know) (2018) J Endocrinol Invest, , [E Pub ahead of print]",
year = "2020",
doi = "10.1007/s40618-019-01112-8",
language = "English",
volume = "43",
pages = "337--345",
journal = "J. Endocrinol. Invest.",
issn = "0391-4097",
publisher = "Springer",
number = "3",
}